Company intelligence / Profile preview
Kinomedica
Melbourne, Victoria, Australia
- Ownership
- Private
- Development stage
- Other
01
Overview
Kinomedica is an Australian biotechnology company focused on developing novel therapeutics for metabolic and lifestyle-related diseases, including type 2 diabetes, obesity, muscle atrophy, and nonalcoholic steatohepatitis (NASH). Founded by Professor Mark Febbraio, the company's lead asset is KM-2702 (also known as IC7Fc), a designer chimeric cytokine that selectively activates the gp130 receptor signaling complex. By combining features of interleukin-6 (IL-6) and ciliary neurotrophic factor (CNTF), KM-2702 is engineered to promote beneficial metabolic effects while avoiding the pro-inflammatory pathways typically associated with IL-6 trans-signaling. The company's research has demonstrated promising preclinical efficacy in improving glucose tolerance, preventing weight gain, and reducing liver steatosis and atherosclerosis in animal models.
- Therapeutic areas
- NeurologyEndocrinologyGastroenterologyCardiovascular
- Modalities
- Recombinant fusion proteinBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Monash UniversityGarvan Institute of Medical ResearchBaker Heart and Diabetes Institute
Beyond the preview
Go deeper on Kinomedica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kinomedica.